Instil Bio Files 8-K with Corporate Updates
Ticker: TIL · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-k
TL;DR
Instil Bio filed an 8-K on Jan 14, 2025, updating corporate info. Check their Dallas HQ address.
AI Summary
Instil Bio, Inc. filed an 8-K on January 14, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 3963 Maple Avenue, Suite 350, Dallas, Texas, 75219, with a phone number of (972) 499-3350. The company is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This filing provides essential corporate information and updates for Instil Bio, Inc., which is relevant for investors and stakeholders tracking the company's operational and financial disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Numbers
- 20250114 — Filing Date (Date of the 8-K filing)
Key Players & Entities
- Instil Bio, Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- 3963 Maple Avenue, Suite 350 (address) — Principal Executive Offices
- Dallas, Texas (location) — Principal Executive Offices City and State
- 75219 (zip_code) — Principal Executive Offices Zip Code
- (972) 499-3350 (phone_number) — Registrant's Telephone Number
- Delaware (location) — State of Incorporation
- 001-40215 (commission_file_number) — SEC File Number
- 83-2072195 (irs_number) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Instil Bio, Inc.?
The primary purpose of this 8-K filing is to report other events and financial statements, along with providing updated corporate information such as the principal executive offices and contact details.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 14, 2025.
Where are Instil Bio, Inc.'s principal executive offices located?
Instil Bio, Inc.'s principal executive offices are located at 3963 Maple Avenue, Suite 350, Dallas, Texas, 75219.
What is Instil Bio, Inc.'s telephone number?
Instil Bio, Inc.'s telephone number is (972) 499-3350.
In which state is Instil Bio, Inc. incorporated?
Instil Bio, Inc. is incorporated in Delaware.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-01-14 07:05:26
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
Filing Documents
- til-20250114.htm (8-K) — 31KB
- pr8-kpressrelease.htm (EX-99.1) — 11KB
- image_0.jpg (GRAPHIC) — 3KB
- 0001789769-25-000003.txt ( ) — 174KB
- til-20250114.xsd (EX-101.SCH) — 2KB
- til-20250114_lab.xml (EX-101.LAB) — 22KB
- til-20250114_pre.xml (EX-101.PRE) — 13KB
- til-20250114_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 14, 2025, Instil Bio, Inc. issued a press release entitled "Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody". A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: January 14, 2025 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)